Drug Database
Back to search

United States· US:70710-1751_1dafee9d-1cc2-41a8-bc75-10cea25fcd0f

JAYTHARI

A deflazacort product containing deflazacort, registered in United States by Zydus Pharmaceuticals (USA) Inc.. The same ATC class is registered in 8 of our 19 countries.

ATC H02AB13

Checked against FDA National Drug Code directory (United States) on

Informational only — not a medical device.

SOURCE REGISTER · USFDA National Drug Code directory (Unite…normalisedJAYTHARIATCH02AB13REGISTER NO.US:70710-1751_1dafee9…PACKS LISTED1CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about deflazacortAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Deflazacort is registered in 8 of 19 countries.

Countries holding a registration under ATC H02AB13 (deflazacort), each read from that country’s own register.

  • This record: United States, from FDA National Drug Code directory (United States)
  • 3 of them publish a price we can compare per daily dose
Search deflazacort products by name

Deflazacort · ATC H02AB13

8 / 19 countries

  • Denmark
  • Finlandprice
  • Germany
  • Netherlands
  • Norwayprice
  • Sweden
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of deflazacort costs, country by country.

Normalised to the WHO defined daily dose (15 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Deflazacort · price per daily dose (15 mg)

USD · FX 28 Sept 2026

  • ES Spain$0.19
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FDA National Drug Code directory (United States)
Active substance
DEFLAZACORT
Manufacturer
Zydus Pharmaceuticals (USA) Inc.
Country
United States (US)
ATC code
H02AB13
ATC class
Deflazacort
Defined daily dose
15 mg, O
Reimbursed
Not published by this register
Source register
FDA National Drug Code directory (United States)
Last checked
September 27, 2026

Packs & prices · 1

  • ndc11
    70710-1751-3

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

434 interactions on record for deflazacort.

Graded by severity as the source publishes them — 129 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check deflazacort against other medicinesHow interaction checks work

Deflazacort · interactions on record

434 records

  • 129 severe
  • 297 moderate
  • 8 minor

Most severe, free to view

  • AprepitantA04AD12severe
  • LonafarnibA16AX20severe
  • DesirudinB01AE01severe
  • BerotralstatB06AC06severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Deflazacort in 7 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All deflazacort products

Authorised across Europe · EMA

The same active substance is authorised in 10 EEA countries. Names it is sold under:

  • Germany · Calcort, Deflazacort Galen
  • Denmark · Deflazacort Vital Pharma Nordic
  • Spain · Defal, Deflazacort Cinfa
  • Finland · Deflazacort Vital Pharma Nordic
  • United Kingdom (Northern Ireland) · Calcort
  • Italy · Decor, Deflan
  • Netherlands · Deflazacort Xgx Pharma
  • Norway · Deflazacort Xgx Pharma
  • Portugal · Deflazacorte Acizan, Deflazacorte Almus
  • Sweden · Deflazacort

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c56330b8-a514-460b-83e6-6ccf9073f7bd
GET /v1/drugs/c56330b8-a514-460b-83e6-6ccf9073f7bd?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "route": "ORAL",
  "source": "ndc",
  "strength": "30",
  "substance": "DEFLAZACORT",
  "productndc": "70710-1751",
  "dosage_form": "TABLET",
  "dea_schedule": null,
  "strength_unit": "mg/1",
  "application_number": "ANDA219254",
  "marketing_category": "ANDA"
}
API referenceMCP serverPlans

See everything about deflazacort.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console